DNA interstrand crosslink repair and cancer
By A. Deans, S. West. Nature Reviews. Cancer, 2011
1,002 citations recorded by the source corpus.
Interstrand crosslinks (ICLs) are highly toxic DNA lesions that prevent transcription and replication by inhibiting DNA strand separation. Agents that induce ICLs were one of the earliest, and are still the most widely used, forms of chemotherapeutic drug. Only recently, however, have we begun to understand how cells repair these lesions. Important insights have come from studies of individuals with Fanconi anaemia (FA), a rare genetic disorder that leads to ICL sensitivity. Understanding how the FA pathway links nucleases, helicases and other DNA-processing enzymes should lead to more targeted uses of ICL-inducing agents in cancer treatment and could provide novel insights into drug resistance.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/1b247ee8804f555c7a87d9b24e958c8ea1cb5c9c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Dingfeng Wu
- Chao Ma
- Jun Feng
- Qi Liu
- Jian Fei
- Dandan Huang
- Yi Sun
- Ruixin Zhu
Citations in the corpus
- Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer (2015, positive): “Because mitomycin C is a potent DNA crosslinker and its targets have not been clearly specified 15 , 78 drug pairs among 13 agents were tested as unlabelled samples using RACS (Supplementary Table 4).”